에 대한 최신 뉴스 IGM Biosciences (NASDAQ:IGMS) 주식

IGM Biosciences

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.

Analyst Color

Broad U.S. Equity ETFs

Small Cap

ETFs

EVGO

IGMS

LNTH

MORF

OUST

PLSE

SOUN

iShares Russell 2000 ETF가 추적하는 러셀(Russell) 2000 소형주 지수는 2023년 10월 이후 최고의 주간 실적을 기록하여 6% 이상 급등하여 2022년 1월 이후 최고 수준에 도달했다.

러셀 2000 지수, 연중 가장 강한 주를 기록하며 31개월 최고치를 기록

IGM Biosciences Inc

UBS analyst Trung Huynh maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and raises the price target from $105 to $110.

News

Price Target

Analyst Ratings

INSM

UBS Maintains Buy on Insmed, Raises Price Target to $110

UBS analyst Roger Boyd maintains Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) with a Buy and raises the price target from $250 to $260.

UBS Maintains Buy on Zscaler, Raises Price Target to $260

Walgreens Boots Alliance Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) shares are trading higher in Thursday&#8217;s after-hours session after the company announced a deal to be <a href="https://in.benzinga.com/general/market-summary/25/03/44102644/walgreens-could-go-private-this-week-after-a-10-billion-deal-with-sycamore-partners-report">acquired by Sycamore Partners</a>.
What Happened: After the market close on Thursday, Walgreens announced it entered into a definitive agreement to be taken private by an entity affiliated with Sycamore Partners for $10 billion.
Walgreens shareholders will receive $11.45 per share in cash at closing. Shareholders are also eligible to receive up to $3 in cash per share from the future monetization of Walgreens&#8217; debt and equity interests in VillageMD, which includes the Village Medical, Summit Health and CityMD businesses.
&#8220;While we are making progress against our ambitious turnaround strategy, meaningful value creation will take time, focus and change that is better managed as a private company. Sycamore will provide us with the expertise and experience of a partner with a strong track record of successful retail turnarounds,&#8221; said Tim Wentworth, CEO of Walgreens.
&#8220;The WBA Board considered all these factors in evaluating this transaction, and we believe this agreement provides shareholders premium cash value, with the ability to benefit from additional value creation going forward from monetization of the VillageMD businesses.&#8221;
See Also: <a href="https://www.benzinga.com/news/earnings/25/03/44181200/broadcom-stock-surges-on-q1-earnings-beat-revenue-beat-strong-guidance-we-expect-continued-strength-in-ai-semiconductor-revenue">Broadcom Stock Surges On Q1 Earnings Beat, Revenue Beat, Strong Guidance: &#8216;We Expect Continued Strength In AI Semiconductor Revenue&#8217;</a>
Walgreens&#8217; board unanimously approved the proposed transaction, which is expected to close in the fourth quarter of 2025. Upon completion of the transaction, Walgreens will become a private company and the company&#8217;s common stock will be delisted from the Nasdaq.
Walgreens noted it will release its <a href="https://www.benzinga.com/calendars/earnings">second-quarter financial results</a> on April 8. Analysts currently expect the company to report earnings of 52 cents per share and revenue of $38.04 billion, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
WBA Price Action: <a href="http://benzinga.com/quote/wba">Walgreens shares</a> were up 5.85% after hours, trading at $11.22 at the time of publication Thursday, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Courtesy of Walgreens Boots Alliance.

After-Hours Center

Movers

Walgreens Stock Rises As Company Inks $10B Deal To Go Private

Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) has outperformed the market over the past 20 years by 5.67% on an annualized basis producing an average annual return of 13.79%. Currently, Gilead Sciences has a market capitalization of $144.34 billion. 
Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,300.17 today based on a price of $115.90 for GILD at the time of writing.
<h3>Gilead Sciences's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741302909_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

GILD

Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years

Retirement planning isn't exactly the most exciting topic. Until you realize you can actually get free money for investing in your future. <a href="https://www.benzinga.com/money/robinhood-review">Robinhood</a> is flipping the script on IRAs with an offer that's hard to ignore. Earn 3% extra on annual contributions when you <a href="https://www.benzinga.com/go/robinhood-gold-credit-card">subscribe to Robinhood Gold</a>, plus an uncapped 2% boost on transfers and rollovers until April 30. 
<ul>
<li><a href="https://www.benzinga.com/go/robinhood-retirement">Sign up for a Robinhood Retirement account now</a></li>
</ul>
<h2 class="wp-block-heading">Why Settle for Ordinary When You Can Boost Your IRA?</h2>
You work hard for your money, so why not make it work harder for you? With <a href="https://www.benzinga.com/go/robinhood-retirement">Robinhood's IRA</a>, every contribution gets an instant 3% boost when you&#8217;re a Robinhood Gold subscriber. And if you're rolling over funds from another retirement account, you'll get a 2% boost. No cap, no gimmicks, just extra cash added to your investments.
If you're serious about maxing out your IRA for 2025, there's another sweet deal: contribute the full amount by April 15, 2025, and you could snag an extra $420 in matching funds.
<h2 class="wp-block-heading">The Robinhood IRA Advantage</h2>
This isn't just another IRA. Robinhood is rewriting the rules with a platform built for simplicity, flexibility, and more money in your pocket.
<h3 class="wp-block-heading">Tax Advantages That Keep More Money in Your Pocket</h3>
Your <a href="https://www.benzinga.com/money/how-to-invest-your-ira">earnings in an IRA</a> grow tax-deferred or tax-free, depending on whether you choose a Traditional or Roth IRA. That means more of your money stays invested, compounding over time instead of going to the <a href="https://www.irs.gov/">IRS</a>.
<h3 class="wp-block-heading">Options Trading in a Tax-Advantaged Account</h3>
Not ready to retire from active investing? Robinhood lets qualified traders trade options on stocks and ETFs inside their IRA, with no commission or per-contract fees. That means you get the flexibility of options trading without the tax hit you'd face in a traditional brokerage account.
<h3 class="wp-block-heading">Already Have a 401(k)? Stack an IRA on Top</h3>
A 401(k) is great, but it might not be enough. If you're already maxing out your employer-sponsored plan, you can still contribute up to $7,000 in an IRA for 2025. More investment, more tax advantages, and with Robinhood, more free money with every contribution.
<h3 class="wp-block-heading">One Platform for Everything</h3>
Tired of tracking retirement accounts across different platforms? Robinhood makes it easy to find and consolidate your retirement savings in one place. Whether you&#8217;re rolling over an old 401(k) or moving funds from another IRA, the process is simple, fast, and now comes with a 2% cash boost on all transfers.
<h2 class="wp-block-heading">Who Should Consider a Robinhood IRA?</h2>
<ul>
<li>Investors who want more money upfront. Get an instant 3% boost on contributions</li>
<li>People who already <a href="https://www.benzinga.com/money/how-to-invest-your-401k">max out a 401(k)</a>. Stack an IRA on top for even greater tax benefits</li>
<li>Anyone looking for low-cost, commission-free investing. No hidden fees or per-contract costs</li>
<li>Self-employed workers or freelancers. No employer 401(k)? No problem. Robinhood's IRA puts you in control</li>
<li>Long-term investors who want to grow wealth tax-efficiently. Keep more of your gains over time</li>
</ul>
<h2 class="wp-block-heading">The Clock is Ticking</h2>
This isn't a forever deal. That 2% unlimited transfer boost disappears after April 30, and the $420 max-out match is only available if you contribute by April 15, 2025. The 3% instant match is here to stay for Robinhood Gold subscribers, but why wait? The sooner you contribute, the more time your money has to grow.
<ul>
<li><a href="https://www.benzinga.com/go/robinhood-retirement">Sign up for a Robinhood Retirement account now</a></li>
</ul>
Over 1,000,000 people have trusted Benzinga to help them choose their investing tools. Our experts are hard at work with constant updates as products &amp; markets change! Benzinga is a reader-supported publication. We may earn a commission from the advertisers associated with this article. This article is not sponsored.

Personal Finance

Robinhood's Retirement Account Just Got Even More Interesting

Maxim Group analyst Matthew Galinko downgrades Arbe Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBE#NASDAQ">ARBE</a>) from Buy to Hold.

Downgrades

ARBE

Maxim Group Downgrades Arbe Robotics to Hold

Lake Street analyst Frank Takkinen maintains Sight Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGHT#NASDAQ">SGHT</a>) with a Hold and lowers the price target from $3 to $2.5.

SGHT

Lake Street Maintains Hold on Sight Sciences, Lowers Price Target to $2.5

Lake Street analyst Jacob Stephan maintains CompoSecure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPO#NASDAQ">CMPO</a>) with a Buy and lowers the price target from $18 to $15.

CMPO

Lake Street Maintains Buy on CompoSecure, Lowers Price Target to $15

Lake Street analyst Jaeson Schmidt maintains Identiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVE#NASDAQ">INVE</a>) with a Buy and lowers the price target from $7 to $6.

INVE

Lake Street Maintains Buy on Identiv, Lowers Price Target to $6

The Ordinary Shares are expected to begin trading on the NYSE American under the ticker symbol "MCRP" on March 7, 2025. The Offering is expected to close on March 10, 2025, subject to satisfaction of customary closing conditions.

IPOs

MCRP

Micropolis Prices IPO Of 3.875M Ordinary Shares At $4.00 Per Share; To Begin Trading On NYSE American Under Ticker Symbol 'MCRP' On March 7

Jefferies analyst Anthony Petrone maintains Tarsus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARS#NASDAQ">TARS</a>) with a Buy and raises the price target from $54 to $58.

TARS

Jefferies Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $58

The CFPB's dismissal follows its multi-year investigation which began prior to Upbound's acquisition of Acima in 2021. Acima will not pay any money, be required to change any business practices, or be subject to any injunctive or other relief, and the dismissal with prejudice ends the CFPB's challenge to the alleged business practices that were the subject of its investigation and lawsuit.
In connection with the CFPB's determination to drop its claims against Acima, Acima has agreed to dismiss the lawsuit it filed against the CFPB in the United States District Court for the Eastern District of Texas, which challenged the CFPB's authority to pursue those claims against Acima.

Legal

UPBD

Upbound Says Consumer Financial Protection Bureau Has Voluntarily Dismissed Lawsuit Against Its Unit Acima Leasing

Jones Trading analyst Matthew Erdner maintains Real Brokerage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REAX#NASDAQ">REAX</a>) with a Buy and maintains $6 price target.

REAX

Jones Trading Maintains Buy on Real Brokerage, Maintains $6 Price Target

Scotiabank analyst Patrick Colville maintains Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) with a Sector Outperform and raises the price target from $225 to $242.

Scotiabank Maintains Sector Outperform on Zscaler, Raises Price Target to $242

DXP Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXPE#NASDAQ">DXPE</a>) reported quarterly earnings of $1.38 per share which beat the analyst consensus estimate of $0.89 by 55.06 percent. This is a 23.21 percent increase over earnings of $1.12 per share from the same period last year. The company reported quarterly sales of $470.91 million which beat the analyst consensus estimate of $447.00 million by 5.35 percent. This is a 15.69 percent increase over sales of $407.04 million the same period last year.

Earnings

Earnings Beats

DXPE

DXP Enterprises Q4 2024 Adj EPS $1.38 Beats $0.89 Estimate, Sales $470.91M Beat $447.00M Estimate

Trading Halt: Halt status updated at 5:40:00 PM ET: Quotation Resumption: News and Resumption Times

Scotiabank analyst Brandon Bingham maintains Williams Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) with a Sector Perform and raises the price target from $51 to $53.

Scotiabank Maintains Sector Perform on Williams Companies, Raises Price Target to $53

Scotiabank analyst Nicholas Yulico maintains Welltower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) with a Sector Outperform and raises the price target from $165 to $166.

WELL

Scotiabank Maintains Sector Outperform on Welltower, Raises Price Target to $166

Scotiabank analyst Allan Verkhovski maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Sector Perform and raises the price target from $240 to $245.

VEEV

Scotiabank Maintains Sector Perform on Veeva Systems, Raises Price Target to $245

Editor&#8217;s Note: This article has been updated to include a statement from Zelle.
The Consumer Financial Protection Bureau <a href="https://www.benzinga.com/news/legal/24/12/42687945/zelle-became-a-gold-mine-for-fraudsters-consumer-financial-protection-bureau-lawsuit">dropped its lawsuit</a> against JPMorgan Chase &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), Wells Fargo &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) and Bank of America Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) on Tuesday concerning the banks&#8217; alleged failure to prevent fraud on Zelle. The Trump Administration has <a href="https://www.benzinga.com/news/25/02/44028664/trump-says-he-shut-down-the-ultra-left-cfpb-after-bankers-and-loan-officers-called-him-almost-crying">wound down CFPB cases</a> in recent weeks.
What Happened: The agency dismissed its case against the banks and Early Warning Services, Zelle&#8217;s parent company, CNBC <a href="https://www.cnbc.com/2025/03/04/cfpb-drops-jpmorgan-bank-of-america-wells-fargo-lawsuit.html">reports</a>. The lawsuit was originally brought in December during the Biden Administration.
The lawsuit alleged that banks did not do enough to protect and reimburse consumers from fraud on Zelle. The defendants allegedly rushed to launch Zelle without implementing sufficient anti-fraud protections. Because the cases were dismissed with prejudice, the agency will not bring similar charges against the banks again.
A Zelle spokesperson said, "We welcome the CFPB's decision to drop its lawsuit against the Zelle network. As we've said before, this lawsuit was without merit and legally and factually flawed. We look forward to continuing to provide Zelle, a trusted service, to 151 million enrolled American consumer and small business accounts."
The CFPB&#8217;s December <a href="https://files.consumerfinance.gov/f/documents/cfpb_Zelle-Complaint_2024-12.pdf">filing</a> said that 210,000 Bank of America customers experienced over $290 million in collective losses, 420,000 Chase customers lost over $360 million and 280,000 Wells Fargo customers were defrauded of over $220 million since 2017.
Reactions: The Trump administration has ended several consumer protection cases in recent weeks. Elon Musk, senior advisor to Trump, previously <a href="https://x.com/elonmusk/status/1861644897490751865">said</a> he&#8217;d like to &#8220;delete&#8221; the CFPB.
The CFPB&#8217;s <a href="https://www.consumerfinance.gov/about-us/the-bureau/" target="_blank" rel="noopener">mission</a> is to &#8220;protect consumers from unfair, deceptive, or abusive practices and take action against companies that break the law.&#8221;
Political figures reacted to the cases dropped by the agency.
&#8220;The CFPB makes up just 0.01% of the federal budget, yet it has returned $21 BILLION to American taxpayers,&#8221; Congressman Bill Foster (D-IL) <a href="https://x.com/RepBillFoster/status/1896672481190023622">said</a>. &#8220;Still, Trump &amp; Musk want to shut it down and make it easier for scammers to rip you off.&#8221;
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44110273/trump-tariffs-will-raise-prices-within-days-target-ceo-says">Trump Tariffs Will Raise Prices &#8216;Within Days,&#8217; Target CEO Says</a></li>
</ul>
Photo: Shutterstock

Equities

Government

CFPB Drops Zelle Fraud Reimbursement Case Against JPMorgan, Wells Fargo (UPDATED)

Press Releases

IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update

Treatment.com AI Inc. (TRUE.CN) Advances AI in Healthcare with Strategic Moves

Health Care

IGM Biosciences to Present at the Jefferies Healthcare Conference

IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update

IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit

IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity

IGM Biosciences to Present at Three Upcoming Investor Conferences

IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update

IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS

AKTS

BNED

CSE:TRUE

GWAV

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Adicet Bio

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Avalo Therapeutics

Cabaletta Bio

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Citius Oncology

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

HilleVax

TuHURA Biosciences

I-MAB

Inozyme Pharma

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Lexeo Therapeutics

Metagenomi

MediciNova

PepGen

Regulus Therapeutics

Skye Bioscience

Vistagen Therapeutics, Inc. - Common Stock

Vistagen Therapeutics

Zura Bio Limited - Class A Ordinary shares

Zura Bio

Jefferies

Truist Securities

Stifel

RBC Capital

BMO Capital

iShares Russell 2000 ETF가 추적하는 러셀(Russell) 2000 소형주 지수는 2023년 10월 이후 최고의 주간 실적을 기록하여 6% 이상 급등하여 <a href="https://www.benzinga.com/topic/small-caps" target="_blank" rel="noopener" data-google-interstitial="false">2022년 1월 이후</a> 최고 수준에 도달했다.
이러한 랠리는 주로 목요일 세션에 의해 주도되었으며, 러셀 2000 지수는 일일 3.6%라는 놀라운 상승률을 기록했다. 이번 급등은 예상보다 낮은 6월 인플레이션 데이터에 따른 것이며, 이로 인해 잠재적인 금리 인하 가능성에 대한 기대가 강화되었다.
그러나 LPL 파이낸셜의 최고 글로벌 전략가인 퀸시 크로스비(Quincy Krosby)는 러셀 2000의 금리 인하 메시지가 &#8220;노동 시장에 대한 연방준비제도(연준)의 우려로 인해 흐려질 수 있다&#8221;고 시사하면서 주의를 조언했다.
크로스비는 노동시장 약화가 경제적으로 민감한 러셀 2000 지수에 여전히 타격을 줄 것이며, 금리 인하가 반드시 더 광범위한 경기 둔화로부터 지수를 보호할 수는 없을 것이라고 생각한다.
<h2 class="wp-block-heading">이번 주의 차트: 8개월 만에 최대 성과를 올린 소형주 지수</h2>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-434094" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-1024x488.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-1024x488.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-300x143.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-768x366.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-1536x732.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21.png 1920w" alt="" width="1024" height="488" /></figure>
출처: <a href="URL http://www.benzinga.com/pro/register/?utm_source=BZprocontent071224&amp;t=be2bearmibe3na1">Benzinga Pro</a>
러셀 2000의 인상적인 성과는 투자자들이 거대 기술 기업들에서 벗어나 더 넓은 시장으로 직접 유입됨에 따라 금리에 민감한 중소형주가 이익을 얻는 등 시장 초점의 상당한 변화를 강조한다고 크로스비가 강조했다.
이 분석가는 러셀 2000이 잠재적인 금리 완화와 광범위한 경제 상황에 대한 중요한 지표 역할을 한다고 지적했다. 일반적으로 중소형주 유니버스는 매력적인 밸류에이션에도 불구하고 심각한 경기 둔화 조짐이 보이면 매도할 것이다.
"역사적으로 러셀 2000은 첫 번째 금리 인하 이후 3개월 동안 시장보다 뒤쳐졌다. 연준이 일반적으로 경제, 특히 노동 시장에 대한 우려로 금리를 인하하기 때문이다. 파월 의장은 연준의 최대 고용 의무화를 계속해서 주장하면서 연준이 경제 지원을 위해 더 빠른 속도로 금리를 인하할 것이라는 점을 분명히 했다"고 그녀가 말했다.
노동 시장 상황이 악화되면 연준은 예정된 9월 18일 회의보다 더 빨리 완화 주기를 시작할 수도 있다고 크로스비는 말했다. 시장에서는 경기 호조 속에서 인플레이션 완화에 따른 금리 인하를 선호하고 있다.
<h2 class="wp-block-heading">이번 주 러셀 2000에서 가장 높은 성과를 기록한 상위 10개 회사 </h2>
<ol>
<li>모픽 홀딩 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MORF#NASDAQ">MORF</a>): 75.16% (헬스케어)</li>
<li>랜티우스 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>): 55.47% (헬스케어)</li>
<li>IGM 바이오사이언스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGMS#NASDAQ">IGMS</a>): 54.22% (헬스케어)</li>
<li>사운드하운드 AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>): 52.63% (정보기술)</li>
<li>메소드 일렉트로닉스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEI#NASDAQ">MEI</a>): 47.96% (정보기술)</li>
<li>솔라리스 오일필드 인프라스트럭처 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOI#NYSE">SOI</a>): 46.87% (에너지)</li>
<li>펄스 바이오사이언스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>): 45.98% (헬스케어)</li>
<li>아우스터 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NYSE">OUST</a>): 44.21% (정보기술)</li>
<li>EV고 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>): 42.65% (소비자 자유롭게 선택 가능한 소비재)</li>
<li>선런 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>): 42.51% (산업재)</li>
</ol>
지금 읽기:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/07/39750466/us-consumer-morale-dips-more-than-expected-in-july-sentiment-remains-stubbornly-subdued">미국 소비자 심리, 7월 예상보다 감소&#8230;전망은 &#8216;완고하게 억제된 상태&#8217;</a></li>
</ul>
사진: 셔터스톡
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

IGM Biosciences

뉴스

에 대한 최신 뉴스 IGM Biosciences (NASDAQ:IGMS) 주식

금요일, 7월 12, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌